The global heart attack diagnostics market size is expected to reach USD 18.52 billion by 2030, according to a new report by Grand View Research, Inc. The heart attack diagnostics market is anticipated to grow at a CAGR of 8.2% during the forecast year from 2024 to 2030. The overall risk factors and the disease burden remains large, thereby rendering the heart attack diagnostic sectors a profitable growth prospect. This growth is attributed to a majority of factors, such as high prevalence of coronary heart diseases, increased tobacco smoking, and obesity, enhanced adoption of unhealthy diet is resulting in a high cholesterol incidence in individuals, particularly in the rising geriatric population. However, the low Medicare reimbursement provided for the mobile cardiac outpatient telemetry electrocardiogram (ECG) and the progressively declining heart attack incidence rates are expected to hamper the market growth.
The heart attack diagnostics market has been classified by product into electrocardiogram, which measures the electrical activity of the heart; echocardiogram, a form of ultrasound test that provides images of the heart; blood tests that measure the expression of certain proteins in excess, such as troponin levels, and cardiac enzymes; and other diagnostic products. The ECG segment is expected to witness a significant growth rate in developing countries, owing to the technological advances coupled with increasing applications of ECG. Although, the increasing demand for cost effective, rapid blood tests such as troponin and Creatine Kinase MB Isoenzyme (CK-MB) is likely to acquire major market share in the near future. The key countries landscape included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa, and Middle East. The Asia Pacific region is anticipated to be the fastest growing region during the forecast period. On the other hand, North America is estimated to dominate the global heart attack diagnostics market.
Request a free sample copy or view report summary: Heart Attack Diagnostics Market Report
North America is estimated to dominate the global heart attack diagnostics market. The increasing awareness about heart attacks, its causative and risk factors, and enhanced uptake and acceptance of technologically advanced diagnostics is expected to contribute to the market growth.
The Asia Pacific region is expected to be the fastest growing region during the forecast period. to The reason being the considerably large burden of heart diseases in certain developing regions, such as in India, where 2.4 million people die annually due to heart diseases. As a result of the soaring incidences of heart diseases, an urgent requirement to undertake awareness measures and incorporate advanced diagnostics is expected to fuel the market growth.
The Troponin segment dominated the blood tests market and accounted for a share of 62.5% in 2023. Troponin T, a protein present in the heart muscle, is crucial in diagnosing heart attacks through a high-sensitivity troponin T test.
Grand View Research has segmented the global heart attack diagnostics market report based on test, end use, and region:
Heart Attack Diagnostics Test Outlook (Revenue, USD Billion, 2018 - 2030)
Electrocardiogram
Blood Test
Troponin
CK-MB
Others
Heart Attack Diagnostics End-use Outlook (Revenue, USD Billion, 2018 - 2030)
Hospitals
Ambulatory Surgical Centers
Others
Heart Attack Diagnostics Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Heart Attack Diagnostics Market
GE Healthcare
Hitachi Corporation
Koninklijke Philips NV
Midmark Corporation
F Hoffmann-La Roche Ltd
Schiller AG
Siemens Healthineers
Toshiba Corporation
Welch Allyn Inc
Astrazenca PLC
"The quality of research they have done for us has been excellent..."